Cornista Alyssa Mauri, Giolito Maria Virginia, Baker Kristi, Hazime Hajar, Dufait Inès, Datta Jashodeep, Khumukcham Saratchandra Singh, De Ridder Mark, Roper Jatin, Abreu Maria T, Breckpot Karine, Van der Jeught Kevin
Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, Florida.
Department of Biomedical Sciences, Vrije Universiteit Brussel, Laboratory for Molecular and Cellular Therapy, Brussels, Belgium.
Gastro Hep Adv. 2023;2(8):1103-1119. doi: 10.1016/j.gastha.2023.09.007. Epub 2023 Sep 19.
Cancer immunotherapy has become an indispensable mode of treatment for a multitude of solid tumor cancers. Colorectal cancer (CRC) has been one of the many cancer types to benefit from immunotherapy, especially in advanced disease where standard treatment fails to prevent recurrence or results in poor survival. The efficacy of immunotherapy in CRC has not been without challenge, as early clinical trials observed dismal responses in unselected CRC patients treated with checkpoint inhibitors. Many studies and clinical trials have since refined immunotherapies available for CRC, solidifying immunotherapy as a powerful asset for CRC treatment. This review article examines CRC immunotherapies, from their foundation, through emerging avenues for improvement, to future directions.
癌症免疫疗法已成为多种实体肿瘤癌症不可或缺的治疗方式。结直肠癌(CRC)是众多受益于免疫疗法的癌症类型之一,尤其是在晚期疾病中,标准治疗无法预防复发或导致生存率低下的情况下。免疫疗法在CRC中的疗效并非没有挑战,因为早期临床试验观察到,接受检查点抑制剂治疗的未经筛选的CRC患者反应不佳。此后,许多研究和临床试验对CRC可用的免疫疗法进行了改进,巩固了免疫疗法作为CRC治疗有力手段的地位。这篇综述文章探讨了CRC免疫疗法,从其基础,到新出现的改进途径,再到未来方向。